There's still time to register for the Clinical Vaccinology Update (CVU) 2021!

There's still time to register for the Clinical Vaccinology Update (CVU) 2021 taking place virtually on Thursday 18th and Friday 19th November.

This 2-day virtual program will allow participants to choose from keynote sessions delivered on our virtual main stage in addition to themed seminars and interactive workshops hosted by industry experts, addressing the most important issues in immunisation.

To find out more about the program and to register, please click on the link below to our Events page:
MVEC: Clinical Vaccinology Update (CVU) 2021


Moderna's COVID-19 vaccine (SPIKEVAX) - provisional determination granted for proposed use in children and booster shot for adults under evaluation

The Therapeutic Goods Administration (TGA) has granted provisional determination to Moderna Australia Pty Ltd in relation to its COVID-19 vaccine, SPIKEVAX.

SPIKEVAX is provisionally approved for use in individuals 12 years of age or older. The granting of this determination means that Moderna Australia Pty Ltd is eligible to apply to vary the provisional approval for the vaccine for use in younger children.

要阅读更多信息,请点击以下链接:
Moderna's COVID-19 vaccine (SPIKEVAX) - provisional determination granted for proposed use in children and booster shot for adults under evaluation


New immunisation reference page: COVID-19 vaccine compensation scheme

The No Fault COVID-19 Indemnity Scheme is a Commonwealth government funded initiative that has been  introduced to allow Australians who have been significantly impacted by an adverse event following a COVID-19 vaccine to apply for financial assistance.

Our new reference page outlines the No Fault COVID-19 Indemnity Scheme, including which vaccines are covered under the scheme, and how to make a claim.

要了解更多信息,请点击以下链接:
MVEC: COVID-19 vaccine compensation scheme

 


Reminder to register for the Clinical Vaccinology Update (CVU) 2021!

A reminder to register for the Clinical Vaccinology Update (CVU) 2021 taking place virtually on Thursday 18th and Friday 19th November.

This 2-day virtual program will allow participants to choose from keynote sessions delivered on our virtual main stage in addition to themed seminars and interactive workshops hosted by industry experts, addressing the most important issues in immunisation.

To find out more about the program and to register, please click on the link below to our Events page:
MVEC: Clinical Vaccinology Update (CVU) 2021


The Conversation: COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far

This week, the US Food and Drug Administration (FDA) has authorised the provisional use of the Pfizer COVID-19 vaccine in children between the age of 5 to 11 years. Children will receive two doses of the vaccine, at a reduced dose (one-third of the adult dose) administered approximately three weeks apart.

Pfizer has submitted a partial application to Australia’s Therapeutic Goods Administration (TGA) and is currently on track to supply the remaining data over the next two weeks. Once approved, the Australian Technical Advisory Group on Immunisations (ATAGI) will advise the government on timing the rollout.

Current data suggests a clear advantage to immunising children against COVID-19, including protecting them from severe complications associated with the Delta variant, and helping to minimise the spread of the virus amongst the more vulnerable in the community.

Follow this link to read the full article:

COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far

 


Advice on returning Australian children

ATAGI have provided COVID-19 vaccination advice for children aged 12 years and over returning to Australia from overseas.

In an effort to keep families together, New South Wales, Victoria and the Australian Capital Territory have agreed to apply an exemption for those Australians aged 12–17 to arrive from overseas who are not fully vaccinated (have received 2 doses of a TGA recognised COVID-19 vaccine, adhering to the recommended dosing interval).

Affected children will be required to undertake a test within 24 hours of arrival into Australia and quarantine at home for 7 days. A second test will be required on day 5 prior to completion of quarantine. They may attend school after completing 7 days home quarantine. Additionally, 12–17 year olds not fully vaccinated will not be allowed to visit other high risk settings such as disability facilities, aged-care residential facilities and hospitals until 14 days after arrival.

To read the statement in full, please click on the link below:
Returning Australian children